<DOC>
	<DOCNO>NCT01957202</DOCNO>
	<brief_summary>This study randomise , double blind , placebo control , 3-way , incomplete block crossover study evaluate effect single repeat dos levocabastine , FF , placebo FDC FF/levocabastine administration AR subject . The total expect study duration individual participating study maximum 20 week ( include screen follow-up ) . This three period study subject assign sequence three treatment . There wash-out period 14-28 day two treatment period . The rational study demonstrate proof concept FDC FF levocabastine compare component administer alone .</brief_summary>
	<brief_title>A Proof Concept Study Assess Effect Fluticasone Furoate ( FF ) /Levocabastine Fixed Dose Combination ( FDC ) Compared With Levocabastine FF Alone Subjects With Allergic Rhinitis ( AR )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Levocabastine</mesh_term>
	<criteria>Diagnosis AR , determine presence rhinitis symptom last several month per year , 1 year attribute infection nasal abnormality . Subjects TNSS score &gt; =6 screen allergen challenge chamber . Subjects positive skin prick test ( wheal &gt; =4 millimeter [ mm ] ) seasonal pollen within 12 month precede screen visit . Subjects positive radioallergosorbent test ( RAST ) ( &gt; =class 2 ) seasonal pollen within 12 month precede screen visit . There condition factor would make subject unlikely able stay chamber 5 hour . Male/females 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination laboratory test . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kg body mass index ( BMI ) within range 1930 kilogram per meter suare ( kg/m^2 ) ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] &gt; 40 milli international unit per milliliter ( MIU/milliliter [ mL ] ) estradiol &lt; 40 picogram per milliliter [ pg/mL ] ( &lt; 147 picomole per liter [ pmol/L ] ) confirmatory ) . Childbearing potential negative pregnancy test determine urine betahuman chorionic gonadotropin ( Î²hCG ) test screen prior dosing ; Agrees use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 1 week postlast dose Capable give write informed consent , include compliance requirement restriction list consent form . Subjects nonsmoker , study define smoke &lt; 10 pack per year lifetime , smoke 6 month prior screen visit . alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average correct QT interval ( QTc ) value triplicate electrocardiogram ( ECGs ) obtain brief recording period : Fridericia 's QTC ( QTcF ) &lt; 450 millisecond ( msec ) . Nasal abnormalities likely affect outcome study , nasal septal perforation , nasal polyp , sinusitis nasal malformation . History frequent nose bleeds Patients rhinitis medicamentosa Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Significant renal impairment , base opinion investigator , would preclude subject participation study . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( ~240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>levocabastine fix dose combination , Rhinitis , Allergic , Perennial Seasonal , Allergic Rhinitis , fluticasone furoate</keyword>
</DOC>